Search Within

Martin Stuart Tallman

  1. "2021"
Formats
  1. Journal Article (23)
  2. Meeting Abstract (9)
  3. Review (7)
  4. Editorial (3)
  5. Guidelines (2)
  6. Research Letter (1)
Groups
  1. Adult Leukemia (45)
  2. Center for Hematologic Malignancies (45)
  3. Department of Medicine (45)
  4. Hematologic Malignancies, Division of (45)
  5. Weinberg Fellows (12)
  6. Hematology-Oncology Fellows (10)

More Groups

People
  1. Aaron Goldberg (9)
  2. Maximilian Stahl (7)
  3. Mikhail Roshal (7)
  4. Ross Levine (7)
  5. Andriy Derkach (6)
  6. Eytan Stein (6)

More People

Years
  1. 2021 (45)
Publications
  1. Blood (13)
  2. Leukemia and Lymphoma (6)
  3. Journal of Clinical Oncology (4)
  4. Leukemia (4)
  5. Transplantation and Cellular Therapy (4)
  6. Blood Advances (3)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Taylor & Francis Group (6)
  3. Elsevier Inc. (5)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. Elsevier Ltd (2)

More Publishers

Results (45)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life in patients <=70 years of age with chronic lymphocytic leukemia treated frontline with ibrutinibrituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912
    Meeting Abstract

    Pophali, P. A.; Wang, X. V.; Zhao, F.; Kay, N. E.; Hanson, C. A.; Thomas, M. L.; O'Brien, S. M.; Barrientos, J.; Paietta, E. M.; Leis, J. F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic transplantation in fit older adults is feasible and encouragingly efficacious. Post remission data from the prospective ECOG-ACRIN (E2906) clinical study
    Meeting Abstract

    Ofran, Y.; Sun, Z.; Rowe, J. M.; Claxton, D. F.; Tallman, M. S.; Arber, D. A.; Melnick, A.; Levine, R. L.; Paietta, E.; Godwin, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Enrollment characteristics and outcomes of Hispanic and Black AYA ALL patients enrolled on a US Intergroup clinical trial: A comparison of the CALGB 10403 (alliance) cohort with us population-level data
    Meeting Abstract

    Muffly, L.; Yin, J.; Jacobson, S.; Advani, A.; Luger, S. M.; Tallman, M. S.; Litzow, M. R.; Foster, M. C.; Appelbaum, F. R.; Larson, R. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Risks for hospitalization and death among patients with blood disorders from the ASH RC COVID-19 Registry for Hematology
    Meeting Abstract

    Hicks, L. K.; Redd, R. A.; Anderson, K. C.; Desai, P.; Dolan, B.; Goldberg, A. D.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Sehn, L. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of secondary acute myeloid leukemia with mixed phenotype
    Meeting Abstract

    Galera, P.; Chan, A.; Derkach, A.; Liu, Y.; Baik, J.; Famulare, C.; Sigler, A.; Arcila, M. E.; Mata, D. A.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Patients with AML who achieve long term complete remission do not have a normal life expectancy when compared to the general population. Analysis of 3,012 patients enrolled on 9 consecutive ECOG-ACRIN trials
    Meeting Abstract

    Ganzel, C.; Roopcharan, K.; Sun, Z.; Rowe, J. M.; Fernandez, H. F.; Paietta, E. M.; Luger, S. M.; Lazarus, H. M.; Cripe, L. D.; Douer, D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) data hub
    Meeting Abstract

    Desai, P.; Goldberg, A. D.; Anderson, K. C.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Redd, R. A.; Roboz, G. J.; Sehn, L. H.; Sekeres, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Editorial

    Bewersdorf, J. P.; Stone, R. M.; Tallman, M. S.; Stahl, M.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save